Background
Contemporary risk scores for ischemic or bleeding event prediction after drug-eluting stent (DES) implantation are limited to the determination of single time duration for dual antiplatelet therapy (DAPT) and lack flexibility in providing dynamic risk stratification.
Objectives
This study sought to develop artificial intelligence (AI) models to dynamically predict the ischemic and bleeding risks at different time intervals for patients with DES implantation for personalized decision support for antiplatelet therapy.
Methods
We identified 81,594 adult patients who received DES implantation in the United States from the Cerner HealthFacts; dataset. The total prediction window covered 12-30 months after DES implantation. We designed eight prediction scenarios with four prediction intervals (3, 6, 12, and 18 months). Five AI models were developed for the ischemic and bleeding risk stratification. Model performance was assessed using the area under the receiver operating characteristic curve (AUROC).
Results
Our proposed AI model outperformed the clinical guideline-recommended tool--the DAPT score--for 12m-30m prediction (with AUROC 0.82 vs. 0.79 for ischemia, 0.77 vs 0.72 for bleeding). In the scenarios that are not covered by the DAPT score, our models demonstrated robust performance (AUROC ranges were 0.79-0.80 for ischemia and 0.75-0.76 for bleeding).
Conclusions
As the first effort dedicated to dynamically forecasting adverse endpoints after DES implantation given DAPT continuation or discontinuation, our AI-empowered approach demonstrates superior capabilities for risk stratification, holding value as a novel clinical tool that can refine the prognostic judgments of clinicians and achieve optimal DAPT management.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.